A Report of the Association for Molecular Pathology

From the Whole Genome Analysis Working Group, Association for Molecular Pathology Clinical Practice Committee,* Bethesda, Maryland; the Departments of Pathology and Pediatrics, Stanford University School of Medicine, Stanford, California; the Department of Transformation Program Office, College of American Pathologists, Northfield, Illinois; the Department of Clinical Diagnostics, Sequenom Center for Molecular Medicine, Grand Rapids, Michigan; the Department of Molecular Medicine, Life Technologies, Foster City, California; the Department of Pathology, Virginia Commonwealth University, Richmond, Virginia; the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska; the Department of Pathology and Laboratory Medicine, University of California, Los Angeles School of Medicine, Los Angeles, California; Illumina Clinical Services Lab, San Diego, California; the Division of Laboratory Science and Standards, Centers for Disease Control and Prevention, Atlanta, Georgia; the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Molecular Oncology, BloodCenter of Wisconsin, and the Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin; the Department of Pathology and Laboratory Medicine,* Weill Cornell Medical College, New York, New York; the Department of Pathology, University of Utah/ARUP Laboratories, Salt Lake City, Utah; Esoterix Genetic Laboratories, LLC, Westborough, Massachusetts; Molecular Genetics, Quest Diagnostics, Nichols Institute, Chantilly, Virginia; the American Society of Investigative Pathology, Bethesda, Maryland; the Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah; the ARUP Institute for Experimental and Clinical Pathology, Salt Lake City, Utah; and the Department of Clinical Sciences–Pathology, University of Central Florida College of Medicine, Orlando, Florida